Dermatophyte antifungal susceptibility in Faisalabad: terbinafine and itraconazole MICs
Official title: In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
Run by Allied Hospital Faisalabad · NCT07898475 · Data updated 2026-11-12
This study tests how common skin fungus infections in Faisalabad respond to terbinafine and itraconazole by measuring the lowest drug levels that stop growth in patient samples.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Allied Hospital Faisalabad Academic / other |
| Locations | 1 site (Faisalabad, Punjab Province) |
| Status | Recruiting |
| Started | October 2, 2026 |
| Main results expected | April 2027 |
| Study ends | May 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07898475 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with clinically suspected dermatophytosis confirmed by KOH microscopy, across all ages and both sexes, who have not used systemic antifungals or recent topical/systemic antifungals within 2 weeks.
✕Probably not a fit
Patients whose infections are caused by fungi not tested in this study or who have recent antifungal exposure outside inclusion criteria may not benefit from the testing.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, cross-sectional study collects dermatophyte samples from patients with clinically confirmed infections and tests each isolate for susceptibility to terbinafine and itraconazole using the CLSI M38 broth microdilution method. The goal is to describe MIC distributions, identify elevated terbinafine MICs, and explore associations with clinical features such as disease duration, prior antifungal use, and topical corticosteroid exposure. No treatment changes result from participation; only laboratory testing of isolates is performed. Data on demographics, clinical type, and exposure history are recorded, and isolates are identified by culture and morphology. The study is conducted at Allied Hospital and Faisalabad Medical University with collaboration from the University of Agriculture Faisalabad.
Why it matters
Potential benefit: If successful, findings could inform local antifungal prescribing practices and help anticipate resistance patterns in Faisalabad.
How similar studies have gone: Prior regional and international work has demonstrated variable terbinafine susceptibility in dermatophytes; this study adds local, contemporary data in Pakistan.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically suspected dermatophytosis confirmed by KOH microscopy * Male and female patients of all age groups * Informed consent from the patient, or from a parent/guardian with child assent for those under 18 years Exclusion Criteria: * Current systemic antifungal therapy, or topical or systemic antifungal use within the previous 2 weeks * Immunocompromised patients * Pregnant or lactating women * Unwilling to participate
Where it's running
-
Allied Hospital, Faisalabad Medical University
Faisalabad, Punjab Province, Pakistan Recruiting
Study contacts
- Principal investigator: Kalsoom Jawaid, MBBS, FCPS, CMT — Faisalabad Medical University
- Study coordinator: Kalsoom Jawaid, MBBS, FCPS, CMT
- Email: dr.klsmjwd@gmail.com
- Phone: +923214470345
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fluconazole versus itraconazole for resistant ringworm (tinea corporis)
This study will test whether oral fluconazole or oral itraconazole works better to clear persistent tinea corporis in adults who have had the infection for at least six months.
-
MMR vaccine injections into lesions for stubborn ringworm of the body and groin (tinea corporis and cruris)
This pilot will test whether injecting the MMR vaccine into affected skin can help people ages 10–60 with tinea corporis or cruris that hasn't responded to standard antifungal treatments.
-
ZYG24004 in tinea pedis: a topical film-forming treatment tested for safety and early effectiveness
A tiny topical medication (ZYG24004) is being tested in adults with athlete's foot to see if it is safe and tolerable and to get a first look at its effect against the fungus.
-
1% tolnaftate stick treatment for tinea pedis (athlete's foot)
This study will test three different 1% tolnaftate stick formulas to see if they are safe and help people aged 16 and older with tinea pedis (athlete's foot).
-
Atmospheric pressure cold plasma treatment for moderate-to-severe athlete's foot
This will test whether atmospheric pressure cold plasma can clear moderate-to-severe tinea pedis (athlete's foot) in adults.
-
Evaluating two products for treating nail fungus
This study is testing a new device for treating nail fungus to see if it works better than an existing product in helping people improve their nail health over nine months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.